Influenza Vaccines

Emergency Human Vaccine Against Hong Kong H5N1 Influenza "Bird Flu" Developed

Published in Vaccine Weekly, February 16th, 1998

Protein Sciences Corp., Meriden, Connecticut, has successfully developed the first experimental human vaccine against the H5N1 "Bird Flu" strain of influenza that recently infected people in Hong Kong and caused significant economic loss in Asia.

The company understands that the vaccine is to be used by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), U.S. National Institutes of Health (NIH) in clinical trials involving laboratory and healthcare workers who are "at risk" from exposure to the virus in the United States and other countries.

The company has delivered more than 1,000 doses of the vaccine to the NIH for use in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1998-02-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry